Back to Mobile View
Subscribe to the CrunchBase Daily for the latest on Fundings, Acquisitions, and Startup Events

Exit

PublicNYSE:LLY
Raised
Post IPO Valuation

General Information

Websitelilly.com
Twitter@Trifexus
CategoryBioTech
Phone317-276-2000
Employees
Founded1876

Offices

Indianapolis, USA
Lilly Corporate Center
Indianapolis, IN, 46285
USA

People

CEO
CFO
President
Managing Director
Financial Analyst

Acquisitions

Total$8B
Avid Radiopharmaceuticals, 11/2010 $800M
Alnara Pharmaceuticals, 7/2010
Imclone Systems, 11/2008 $7.13B
SGX Pharmaceuticals, 7/2008 $66.2M

Investments

Tags

Eli Lilly

Eli Lilly and Company engages in the discovery, development, manufacture, and sale of products in pharmaceutical products business segment. The company manufactures and distributes products through owned or leased facilities in the United States, Puerto Rico, and 25 other countries. Its products are sold in approximately 135 countries. It also conducts research to find products to treat diseases in animals and to increase the efficiency of animal food production. Products Neurosciences products, include: Zyprexa, for the treatment of schizophrenia, acute mixed or manic episodes associated with bipolar I disorder, and bipolar maintenance; Cymbalta, for the treatment of major depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, and in the United States for the management of fibromyalgia; Strattera, for the treatment of attention-deficit hyperactivity disorder in children, adolescents and adults; Prozac, for the treatment of major depressive disorder, obsessive-compulsive disorder, bulimia nervosa and panic disorder; and Symbyax, for the treatment of bipolar depression. Endocrinology products, include: Humalog, Humalog Mix 75/25, and Humalog Mix 50/50tm, for the treatment of diabetes; Humulin, for the treatment of diabetes; Byetta, for the treatment of type 2 diabetes; Actos, for the treatment of type 2 diabetes; Evista, for the prevention and treatment of osteoporosis in postmenopausal women and for the reduction of the risk of invasive breast cancer in postmenopausal women with osteoporosis and postmenopausal women at high risk for invasive breast cancer; Forteo, for the treatment of osteoporosis in postmenopausal women and men at high risk for fracture; and Humatrope, for the treatment of human growth hormone deficiency and idiopathic short stature.

Recent Milestones

Videos

Screenshots

Stock Price

Sources

  1. Lilly to Acquire Avid Radiopharmaceuticals (newsroom.lilly.com) [edit]
  2. Lilly buys Alnara for undisclosed sum (fiercebiotech.com) [edit]
  3. Cap Funding Report (internationallawoffice.com) [edit]
  4. Lilly Announces Completion of SGX Acquisition (sgxpharma.com) [edit]
  5. Sutro Biopharma Secures $26M in Series D Financing (finsmes.com) [edit]
  6. Lilly invests added $20 million in China's Novast (marketwatch.com) [edit]
  7. Eli Lilly backs $250M biotech fund for Asia-Pacific (fiercebiotech.com) [edit]
    Lilly invests £5.4M in R&D hub in U.K. (fiercebiotech.com) [edit]
    Eli Lilly wraps $247M deal for PhII diabetes drug (fiercebiotech.com) [edit]
    Lilly acquires rights to Hutchison MediPharma cancer drug candidate (thepharmaletter.com) [edit]
Edit This Page
Last Edited 4/9/14

Revision History RSS Picture

Sharing

Share this page on Twitter or Facebook:
Or copy this code to embed a widget: customize »

TechCrunch Posts TechCrunch Logo Small Picture

External Links

CrunchBase API

Sponsors



Become a Sponsor
Terms of Service | Privacy Policy | Licensing Policy